TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

BACKGROUND: The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS: We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic muta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Welch, John S., Petti, Allegra A., Miller, Christopher A., Fronick, Catrina C., O'Laughlin, Michelle, Fulton, Robert S., Wilson, Richard K., Baty, Jack D., Duncavage, Eric J., Tandon, Bevan, Lee, Yi-Shan, Wartman, Lukas D., Uy, Geoffrey L., Ghobadi, Armin, Tomasson, Michael H., Pusic, Iskra, Romee, Rizwan, Fehniger, Todd A., Stockerl-Goldstein, Keith E., Vij, Ravi, Oh, Stephen T., Abboud, Camille N., Cashen, Amanda F., Schroeder, Mark A., Jacoby, Meagan A., Heath, Sharon E., Luber, Kierstin, Janke, Megan R., Hantel, Andrew, Khan, Niloufer, Sukhanova, Madina J., Knoebel, Randall W., Stock, Wendy, Graubert, Timothy A., Walter, Matthew J., Westervelt, Peter, Link, Daniel C., DiPersio, John F., Ley, Timothy J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217532/
https://ncbi.nlm.nih.gov/pubmed/27959731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1605949
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares